These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2111726)

  • 41. [HIV and ethics--information and disinformation].
    Högman C
    Lakartidningen; 1992 Oct; 89(41):3341-2. PubMed ID: 1435026
    [No Abstract]   [Full Text] [Related]  

  • 42. HIV infection in two brothers receiving intravenous therapy for hemophilia.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1992 Apr; 41(14):228-31. PubMed ID: 1557013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors.
    Ewing NP; Sanders NL; Dietrich SL; Kasper CK
    JAMA; 1988 Jan; 259(1):65-8. PubMed ID: 3119878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of HCV infection in haemophiliacs treated with a dry-heated factor VIII concentrate.
    Kolho E; Ebeling F; Rasi V
    Thromb Haemost; 1992 Jun; 67(6):728. PubMed ID: 1509419
    [No Abstract]   [Full Text] [Related]  

  • 46. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study.
    Kroner BL; Rosenberg PS; Aledort LM; Alvord WG; Goedert JJ
    J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):279-86. PubMed ID: 8106967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment for evidence of non A-non B hepatitis in patients given n-heptane-suspended heat-treated clotting factor concentrates.
    Carnelli V; Gomperts ED; Friedman A; Aledort L; Hilgartner M; Dietrich S; Fedor EJ
    Thromb Res; 1987 Jun; 46(6):827-34. PubMed ID: 3114910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Preventive treatment of B type hemophilia: comparative evaluation between plasma and a concentrate of factor IX].
    Tribalto M; De Rossi G; Criscuolo D; Roseo I; Guarino S
    Clin Ter; 1975 Aug; 74(3):259-63. PubMed ID: 1227746
    [No Abstract]   [Full Text] [Related]  

  • 49. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group.
    Mannucci PM; Schimpf K; Abe T; Aledort LM; Anderle K; Brettler DB; Hilgartner MW; Kernoff PB; Kunschak M; McMillan CW
    Transfusion; 1992 Feb; 32(2):134-8. PubMed ID: 1311876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship of partially purified factor concentrates to immune tests and AIDS. The Hemophilia-AIDS. Collaborative Study Group.
    Jason J; Holman RC; Evatt BL
    Am J Hematol; 1990 Aug; 34(4):262-9. PubMed ID: 2114785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for the aetiological role of blood-borne virus infections in causing reduced lectin-induced T-cell proliferation in haemophilic boys.
    Evans JA; Pasi KJ; Hill FG
    Br J Haematol; 1995 Sep; 91(1):197-202. PubMed ID: 7577632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis A virus infections associated with clotting factor concentrate in the United States.
    Soucie JM; Robertson BH; Bell BP; McCaustland KA; Evatt BL
    Transfusion; 1998 Jun; 38(6):573-9. PubMed ID: 9661691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate.
    Colombo M; Mannucci PM; Carnelli V; Savidge GF; Gazengel C; Schimpf K
    Lancet; 1985 Jul; 2(8445):1-4. PubMed ID: 2861454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety trial of heated factor VIII concentrate (8Y).
    Pasi KJ; Hill FG
    Arch Dis Child; 1989 Oct; 64(10):1463-7. PubMed ID: 2510607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV seroconversion in haemophilic boys receiving heat-treated factor VIII concentrate.
    Williams MD; Skidmore SJ; Hill FG
    Vox Sang; 1990; 58(2):135-6. PubMed ID: 2111060
    [No Abstract]   [Full Text] [Related]  

  • 56. Appeals court reverses verdict favoring drug companies.
    AIDS Policy Law; 1995 Jun; 10(10):5. PubMed ID: 11362519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemophiliacs with HIV seroconversion associated with heat-treated products: are they actively infected?
    Damjanovic V
    JAMA; 1989 Mar; 261(9):1275. PubMed ID: 2492613
    [No Abstract]   [Full Text] [Related]  

  • 58. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.
    Horowitz MS; Rooks C; Horowitz B; Hilgartner MW
    Lancet; 1988 Jul; 2(8604):186-9. PubMed ID: 2899662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and small-scale production of a severely heated factor VIII concentrate.
    Knevelman A; de Wit HJ; Potstra P; vd Does JA
    Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced risk of non-A, non-B hepatitis after a first exposure to 'wet heated' factor VIII concentrate.
    Kernoff PB; Miller EJ; Savidge GF; Machin SJ; Dewar MS; Preston FE
    Br J Haematol; 1987 Oct; 67(2):207-11. PubMed ID: 3118932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.